MYDURIBEQ Trademark

Trademark Overview


On Friday, April 17, 2020, a trademark application was filed for MYDURIBEQ with the United States Patent and Trademark Office. The USPTO has given the MYDURIBEQ trademark a serial number of 88877213. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, April 13, 2021. This trademark is owned by Celgene Corporation. The MYDURIBEQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
myduribeq

General Information


Serial Number88877213
Word MarkMYDURIBEQ
Filing DateFriday, April 17, 2020
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, April 13, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 16, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Tuesday, April 13, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 16, 2021PUBLISHED FOR OPPOSITION
Wednesday, January 27, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 13, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 9, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 9, 2020NON-FINAL ACTION E-MAILED
Thursday, July 9, 2020NON-FINAL ACTION WRITTEN
Wednesday, July 8, 2020ASSIGNED TO EXAMINER
Monday, April 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, April 21, 2020NEW APPLICATION ENTERED IN TRAM